Assessing thresholds of resistance prevalence at which empiric treatment of gonorrhea should change among men who have sex with men in the US: A cost-effectiveness analysis
PLOS Medicine · 2024
DOI: 10.1371/journal.pmed.1004424 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Medicine, 2024. Verfasst von Xuecheng Yin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Management Science and Information Systems, Spears School of Business, Oklahoma State University, Tulsa, Oklahoma, United States of Ame…. Hauptthemen laut MEDLINE: Gonorrhea, Cost-Benefit Analysis, Anti-Bacterial Agents, Quality-Adjusted Life Years. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: NIAID NIH HHS, CDC, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention.
Abstract (Originalsprache)
Background
Since common diagnostic tests for gonorrhea do not provide information about susceptibility to antibiotics, treatment of gonorrhea remains empiric. Antibiotics used for empiric therapy are usually changed once resistance prevalence exceeds a certain threshold (e.g., 5%). A low switch threshold is intended to increase the probability that an infection is successfully treated with the first-line antibiotic, but it could also increase the pace at which recommendations are switched to newer antibiotics. Little is known about the impact of changing the switch threshold on the incidence of gonorrhea, the rate of treatment failure, and the overall cost and quality-adjusted life-years (QALYs) associated with gonorrhea. Methods and findings We developed a transmission model of gonococcal infection with multiple resistant strains to project gonorrhea-associated costs and loss in QALYs under different switch thresholds among men who have sex with men (MSM) in the United States. We accounted for the costs and disutilities associated with symptoms, diagnosis, treatment, and sequelae, and combined costs and QALYs in a measure of net health benefit (NHB). Our results suggest that under a scenario where 3 antibiotics are available over the next 50 years (2 suitable for the first-line therapy of gonorrhea and 1 suitable only for the retreatment of resistant infections), changing the switch threshold between 1% and 10% does not meaningfully impact the annual number of gonorrhea cases, total costs, or total QALY losses associated with gonorrhea. However, if a new antibiotic is to become available in the future, choosing a lower switch threshold could improve the population NHB. If in addition, drug-susceptibility testing (DST) is available to inform retreatment regimens after unsuccessful first-line therapy, setting the switch threshold at 1% to 2% is expected to maximize the population NHB. A limitation of our study is that our analysis only focuses on the MSM population and does not consider the influence of interventions such as vaccine and common use of rapid drugs susceptibility tests to inform first-line therapy.
Conclusions
Changing the switch threshold for first-line antibiotics may not substantially change the health and financial outcomes associated with gonorrhea. However, the switch threshold could be reduced when newer antibiotics are expected to become available soon or when in addition to future novel antibiotics, DST is also available to inform retreatment regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Management Science and Information Systems, Spears School of Business, Oklahoma State University, Tulsa, Oklahoma, United States of America.
- Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut, United States of America.
- Yale Public Health Modeling Unit, Yale School of Public Health, New Haven, Connecticut, United States of America.
- Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.
- College of Computer Science and Technology/School of Cyber Science and Technology, Zhejiang University, Hangzhou, China.
- Altfest Personal Wealth Management, New York, New York, United States of America.
ORCID-Profile: Xuecheng Yin, Yunfei Li, Minttu M Rönn, Song Li, Joshua A Salomon, Yonatan H Grad, Reza Yaesoubi
Förderung
- NIAID NIH HHS
- CDC
- National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Yin, X., Li, Y., Rönn, M. M., Li, S., Yuan, Y., Gift, T. L., Hsu, K., Salomon, J. A., Grad, Y. H., & Yaesoubi, R. (2024). Assessing thresholds of resistance prevalence at which empiric treatment of gonorrhea should change among men who have sex with men in the US: A cost-effectiveness analysis. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1004424
Vancouver
Yin X, Li Y, Rönn MM, Li S, Yuan Y, Gift TL, et al. Assessing thresholds of resistance prevalence at which empiric treatment of gonorrhea should change among men who have sex with men in the US: A cost-effectiveness analysis. PLOS Medicine. 2024. doi:10.1371/journal.pmed.1004424
BibTeX
@article{Yin2024,
author = {Yin, Xuecheng and Li, Yunfei and Rönn, Minttu M and Li, Song and Yuan, Yue and Gift, Thomas L and Hsu, Katherine and Salomon, Joshua A and Grad, Yonatan H and Yaesoubi, Reza},
title = {Assessing thresholds of resistance prevalence at which empiric treatment of gonorrhea should change among men who have sex with men in the US: A cost-effectiveness analysis},
journal = {PLOS Medicine},
year = {2024},
doi = {10.1371/journal.pmed.1004424}
}
EUVIMED